)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Ondine Biomedical (OBI) investor relations material
Ondine Biomedical H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary26 Sep, 2025
Executive summary
Achieved 18% year-over-year revenue growth in H1 2025, with gross margin up to 65% and over 200,000 patients treated globally, supported by strategic partnerships and commercial expansion in Canada, UK, and EMEA.
Strategic investments in clinical trials, distributor onboarding, and rollout of next-generation products contributed to margin gains and revenue growth.
Net loss widened to $12.6 million for H1 2025, with most sales in Canada and a material uncertainty regarding the ability to continue as a going concern.
Cash and restricted cash at June 30, 2025, totaled $5.6 million, with significant equity raised post-period.
Accumulated deficit reached $298.0 million as of June 30, 2025.
Financial highlights
Revenue for H1 2025 reached $1.01 million CAD, up from $0.86 million CAD in H1 2024 (18% YoY increase), with gross margin at $0.66 million CAD (65% of revenue).
Operating expenses rose to $13.2 million, up 58% year-over-year, mainly due to increased R&D and marketing costs.
Net loss widened to $12.56 million CAD from $7.76 million CAD year-over-year.
Net cash flows from financing activities were $5.5 million in H1, with an additional £11 million (~$21 million CAD) raised post-period.
41% increase in medical facilities using the product and 100% customer retention rate.
Outlook and guidance
Expecting sustained revenue growth in the second half of 2025, with ongoing strategic investments in clinical development and commercial expansion.
Cash runway secured through the end of Q2 2026 following recent funding.
Management believes existing cash and anticipated financings will support operations for at least the next twelve months, but ongoing need to raise additional funds remains.
Anticipate rapid rollout in the U.S. post-FDA approval, leveraging existing hospital relationships.
No specific revenue or hospital increase guidance provided for future years.
What is the cash runway post-Sept 3 financing?
FDA Phase 3 trial progress and next steps?
Barbadian IP contingency update?
U.S. FDA approval timeline and sales initiation?
Mölnlycke's strategy for market expansion?
Post-Phase III R&D cost reduction impact?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Ondine Biomedical Inc. is a life sciences company specializing in the development of photodisinfection-based therapies. These innovative therapies are designed to provide solutions for a wide range of infections, including those resistant to antibiotics. The company's focus is on creating non-antibiotic anti-infective treatments for bacterial, viral, and fungal infections, leveraging its patented light-activated technology. Ondine Biomedical Inc.'s approach represents a significant advancement in addressing the global challenge of drug-resistant infections, offering potential benefits in both healthcare settings and beyond. The company is headquartered in Vancouver, Canada, and its shares are listed on the London Stock Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage